Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF) Chronic Lymphocytic Leukemia (CLL) Diffuse Large B-Cell Lymphoma (DLBCL), Activated B-cell (ABC) Subtype Adult T-Cell Leukemia/Lymphoma (ATLL) Cutaneous T-cell Lymphoma CTCL Mycosis Fungoides Chronic lymphocytic leukemia CLL Diffuse large B-cell lymphoma DLBCL Adult T-cell leukemia/lymphoma ATLL Lymphoma Leukemia Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, Large B-Cell, Diffuse Mycoses Leukemia, T-Cell Leukemia-Lymphoma, Adult T-Cell Lymphoma, T-Cell, Cutaneous Cobomarsen
Lead Scientists at UC Cancer
- Thomas Kipps, MD, PhD (ucsd)
Thomas Kipps, MD, PhD, is Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, and Deputy Director of Research Operations at the UC San Diego Moores Cancer Center. He received his Ph.D. in Immunology and M.D. from Harvard University and had his residency and fellowship training in Internal Medicine, Hematology, and Genetics at Stanford University.
- Herbert Eradat (ucla)
- Lauren Pinter-Brown, MD (uci)
Health Sciences Professor, Medicine
- accepting new patients
- Start Date
- Completion Date
- miRagen Therapeutics, Inc.
- Phase 1
- Study Type
- Last Updated